A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)
Phase of Trial: Phase IV
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms EVALUATE-HF
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 18 Nov 2016 Planned number of patients changed from 402 to 432.
- 06 Sep 2016 Status changed from not yet recruiting to recruiting.